...
首页> 外文期刊>Gene: An International Journal Focusing on Gene Cloning and Gene Structure and Function >Allele-specific silencing of Alzheimer's disease genes - The amyloid precursor protein genes with Swedish or London mutations
【24h】

Allele-specific silencing of Alzheimer's disease genes - The amyloid precursor protein genes with Swedish or London mutations

机译:阿尔茨海默氏病基因的等位基因特异性沉默-具有瑞典或伦敦突变的淀粉样前体蛋白基因

获取原文
获取原文并翻译 | 示例

摘要

Alzheimer's disease (AD) is the most common cause of dementia in humans. A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (A beta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (& 60 years old) of AD. For example, some mutant AM are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate A beta production. The "Swedish" mutations (APP(SW)) and the "London" mutation (APP(LON)) are examples of these mutants. Selective silencing of these mutant alleles holds therapeutic promise for AD. Here we show that the expression of the mutant AM was selectively inhibited by RNA interference. The best selectivity was obtained when the mismatches were centrally placed in the antisense strand of small interfering RNAs. Introducing an additional mismatch in the antisense strand may improve the selectivity. The addition of a G at 5' end of the antisense strand may enhance the efficacy of gene silencing by RNA interference. Our results illustrate the guiding principles for selection of targeted sequences to achieve allele-specific silencing. The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development. (c) 2006 Elsevier B.V. All rights reserved.
机译:阿尔茨海默氏病(AD)是人类痴呆的最常见原因。 AD患者大脑中的病理标志是由淀粉样前体蛋白(APP)的代谢产物累积的β-淀粉样蛋白(A beta)形成的细胞外淀粉样斑块。研究表明,AD的早发家族形式(<60岁)具有很强的遗传联系。例如,一些突变体AM被显着地传播并且与早发AD的遗传分离。这些突变体促进了Aβ的产生。 “瑞典”突变(APP(SW))和“伦敦”突变(APP(LON))是这些突变体的例子。这些突变等位基因的选择性沉默为AD治疗提供了希望。在这里,我们表明突变体AM的表达被RNA干扰选择性地抑制。当错配集中在小干扰RNA的反义链中时,可获得最佳选择性。在反义链中引入额外的错配可以提高选择性。在反义链的5'末端添加G可以增强通过RNA干扰的基因沉默的功效。我们的结果说明了选择靶向序列以实现等位基因特异性沉默的指导原则。如本研究所述,有效沉默APP(SW)和APP(LON)的序列可能在体内和体外研究中均有用,以研究APP(SW)和APP(LON)在AD发育中的病理生理作用。 (c)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号